Bristol Myers Squibb

Bristol Myers Squibb is enhancing its drug discovery capabilities by acquiring NVIDIA’s DGX SuperPOD with Vera Rubin architecture. This investment provides advanced computing power for training AI models, predicting compound behavior, and accelerating therapeutic innovation. The system will democratize access to AI tools for researchers worldwide, significantly streamlining the R&D pipeline and enabling faster, more efficient evaluation of potential drug candidates.